NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012: Proposed Additions and Deletions to the NIOSH Hazardous Drug List
Health and Human Services Department; Centers for Disease Control and Prevention · 2011
Read NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012: Proposed Additions and Deletions to the NIOSH Hazardous Drug List by Health and Human Services Department; Centers for Disease Control and Prevention (2011) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/uslaw-fr-2011-19460.txt.
Description
Notice published in the Federal Register on 2011-08-02 by Health and Human Services Department; Centers for Disease Control and Prevention. Text from federalregister.gov (official edition: govinfo). [FR Doc No: 2011-19460] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention [Docket Number NIOSH-190] NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012: Proposed Additions and Deletions to the NIOSH Hazardous Drug List AGENCY: National Institute for.
Catalog record
| CREATOR | Health and Human Services Department; Centers for Disease Control and Prevention |
|---|---|
| YEAR | 2011 |
| COLLECTION | LAW |
| FORMAT | TXT |
| FILE SIZE | 6 KB |
| VERSION | 1.0 |
| LICENSE | Public Domain |
| RIGHTS | PUBLIC DOMAIN |
| SOURCE | Federal Register |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012: Proposed Additions and Deletions to the NIOSH Hazardous Drug List
Citation: us:fr:2011-19460
Creator: Health and Human Services Department; Centers for Disease Control and Prevention
Year: 2011
Source-URL: https://www.federalregister.gov/documents/2011/08/02/2011-19460/niosh-list-of-antineoplastic-and-other-hazardous-drugs-in-healthcare-settings-2012-proposed
Context: Notice published in the Federal Register on 2011-08-02 by Health and Human Services Department; Centers for Disease Control and Prevention. Text from federalregister.gov (official edition: govinfo).
[FR Doc No: 2011-19460]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Docket Number NIOSH-190]
NIOSH List of Antineoplastic and Other Hazardous Drugs in
Healthcare Settings 2012: Proposed Additions and Deletions to the NIOSH
Hazardous Drug List
AGENCY: National Institute for Occupational Safety and Health (NIOSH)
of the Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of Draft Document Available for Public Comment.
-----------------------------------------------------------------------
SUMMARY: The National Institute for Occupational Safety and Health
(NIOSH) of the Centers for Disease Control and Prevention (CDC)
announces the availability of the following draft document for public
comment entitled ``NIOSH List of Antineoplastic and Other Hazardous
Drugs in Healthcare Settings 2012: Proposed Additions and Deletions to
the NIOSH Hazardous Drug List.'' The document and instructions for
submitting comments can be found at http://www.cdc.gov/niosh/docket/review/docket190/default.html.
This guidance document does not have the force and effect of law.
Public Comment Period: Comments must be received by October 3,
2011.
ADDRESSES: Written comments may be submitted to the NIOSH Docket
Office, identified by Docket Number NIOSH-190, by any of the following
methods:
Mail: NIOSH Docket Office, Robert A. Taft Laboratories,
MS-C34, 4676 Columbia Parkway, Cincinnati, Ohio 45226.
Facsimile: (513) 533-8285.
E-mail: [email protected].
All information received in response to this notice will be
available for public examination and copying at the NIOSH Docket
Office, 4676 Columbia Parkway, Cincinnati, Ohio 45226.
A complete electronic docket containing all comments submitted will
be available on the NIOSH web page at http://www.cdc.gov/niosh/docket,
and comments will be available in writing by request. NIOSH includes
all comments received without change in the docket, including any
personal information provided. All electronic comments should be
formatted as Microsoft Word. Please make reference to Docket Number
NIOSH-190.
SUPPLEMENTARY INFORMATION:
Background: The NIOSH Alert: Preventing Occupational Exposures to
Antineoplastic and Other Hazardous Drugs in Health Care Settings was
published in September 2004 (http://www.cdc.gov/niosh/docs/2004-165/).
This Alert contained Appendix A which was a list of drugs that were
deemed to be hazardous and may require special handling. This list of
hazardous drugs was updated in 2010 and covered all new approved drugs
and drugs with new warning since 2007 (http://www.cdc.gov/niosh/docs/2010-167/). Between June 2007 and December 2009, 48 new drugs received
FDA approval and 115 drugs received special warnings (usually black box
warnings) based on reported adverse effects in patients. The complete
list of these drugs can be found at: http://www.cdc.gov/niosh/docket/review/docket190/pdfs/Proposedchanges07112011.pdf. From this list of
169 drugs, 45 drugs were identified by NIOSH as candidate hazardous
drugs. Seven of these drugs had safe handling recommendations from the
manufacturer and NIOSH is accepting these recommendations as
appropriate. Therefore, these seven drugs will be listed as hazardous
without requiring further review. A panel consisting of peer reviewers
and stakeholders was asked to review and comment on the remaining 38
potentially hazardous drugs. In addition, the panel members were asked
to comment on the removal of 15 drugs from the 2010 Hazardous Drug
List. Reviewers were not asked to provide a consensus opinion and NIOSH
made the final determination regarding additions and deletions to the
2010 hazardous drug List.
NIOSH reviewed the recommendations of the peer reviewers and
stakeholders and determined that 24 drugs in addition to the 7 drugs
with manufacturer's warnings, were determined to have one or more
characteristics of a hazardous drug and this list of 31 drugs is being
published for comment in NIOSH Docket Number 190. In addition, 15 drugs
from the 2010 Hazardous Drug List are being considered for removal.
Four drugs were evaluated for reclassification, two drugs are radio-
pharmaceuticals which are covered by specific handling regulations set
by the Nuclear Regulatory Commission and nine others are not available
in the United States at this time. In order to keep the list as current
as possible, NIOSH will remove any drugs that are no longer available
in the United States. If any of these drugs were to become available at
a later date, NIOSH would reconsider them for review.
FOR FURTHER INFORMATION CONTACT: Barbara MacKenzie, NIOSH, Robert A.
Taft Laboratories, 4676 Columbia Parkway, MS-C26, Cincinnati, Ohio
45226, telephone (513) 533-8132, E-mail [email protected].
Reference: http://www.cdc.gov/niosh/docket/review/docket190/pdfs/PanelSummary05092011.pdf.
Dated: July 22, 2011.
John Howard,
Director, National Institute for Occupational Safety and Health,
Centers for Disease Control and Prevention.
[FR Doc. 2011-19460 Filed 8-1-11; 8:45 am]